Advertisement
Table 5 Joint model estimation on population (N = 2708, 632 recurrent events, 212 deaths)
| Variables (% of women) | Recurrent event | Overall death | ||
|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |
| Estrogen/Progesterone receptor status | ||||
| +/− vs +/+ (18.6%) | 1.40 | 1.10, 1.79 | 2.51 | 1.20, 5.30 |
| −/+ vs +/+ (4.1%) | 1.00 | 0.62, 1.59 | 5.63 | 1.55, 20.46 |
| −/− vs +/+ (15.6%) | 2.14 | 1.70, 2.70 | 9.76 | 4.39, 21.75 |
| Grade | ||||
| moderately differentiated vs well differentiated (36.4%) | 1.61 | 1.15, 2.27 | 3.12 | 0.99, 9.91 |
| poorly differentiated vs well differentiated (48.5%) | 1.90 | 1.36, 2.66 | 6.54 | 2.02, 21.18 |
| Tumor size (≥ 2 cm vs < 2 cm) (20.5%) | 1.64 | 1.33, 2.01 | 4.70 | 2.27, 9.75 |
| Axillary nodal involvement (yes vs no) (30.0%) | 1.54 | 1.26, 1.86 | 5.23 | 2.63, 10.42 |
| Recent MHT use before diagnosis (yes vs no) (44.3%) | 0.75 | 0.62, 0.92 | ||
| Smoking status first follow-up after diagnosis | ||||
| ex-smoker vs never smoker (36.9%) | 1.20 | 1.00, 1.44 | ||
| current smoker vs never smoker (6.5%) | 1.55 | 1.16, 2.07 | ||
| Year of diagnosis | ||||
| 1995–1999 vs 1990–1994 (28.9%) | 0.90 | 0.72, 1.13 | ||
| 2000–2003 vs 1990–1994 (32.3%) | 0.72 | 0.56,0.94 | ||
| 2004–2008 vs 1990–1994 (27.4%) | 0.61 | 0.43, 0.89 | ||
| Age at breast cancer diagnosis (year) | ||||
| [50–60) vs < 50 (44.1%) | 1.80 | 0.68, 4.79 | ||
| [60–70) vs < 50 (38.0%) | 4.50 | 1.29, 15.78 | ||
| ≥ 70 vs < 50 (9.5%) | 9.08 | 1.89,43.69 | ||
| Menopausal status at breast cancer diagnosis | ||||
| postmenopausal woman - no use of MHT vs premenopausal woman (27.1%) | 1.39 | 0.58, 3.32 | ||
| postmenopausal woman-less than 5 years of cumulated MHT use vs premenopausal woman (29.3%) | 0.79 | 0.32, 1.97 | ||
| postmenopausal woman-more than 5 years of cumulated MHT use vs premenopausal woman (28.8%) | 0.35 | 0.11, 1.10 | ||
| θ | 1.01 (σ = 0.05) p-value< 0.001 | |||
| α | 4.29 (σ = 0.77) p-value< 0.001 | |||
